As regulatory reform continues, a more personalized treatment landscape is on the horizon.

Mr. Garnett is a serial entrepreneur and corporate executive with many years of success in founding and leading consumer-packaged-goods and beverage companies in Canada and the United States.

Global Biopharmaceutical Company Hires Leading PR Firm as it Expands Their U.S. Operations.

Over the course of his career, Mr. Pidduck has been involved in the successful ground-up commercialization of several products in both Canadian and international markets and brings a track record of both organic execution as well as M&A and integration expertise.

Boehringer Ingelheim and Lilly launch Hear Your Heart™, an empowering health initiative to provide resources and education for women with heart failure, especially Black and Latina women, to help optimize their care.

Brexit and the pandemic continue to complicate flow of international talent.

Flutura to deploy Cerebra Digital Twin & Pharmacologist Workbench, a self-service AI platform to accelerate impact to Pharmaceutical outcomes.

Bringing together Bristol Myers Squibb and Celgene on one clinical trial management system, company goes live with Vault CTMS in record speed. Modernization streamlines trial management to speed medicines to patients.

Rick Livesay brings over 25 years of healthcare experience to the company to bolster Nava's San Francisco presence.

The agency provides essential support for state-of-the-art engagements, including scientific message platform development, opinion leader identification and more.

New data emerges from release of IQVIA's U.S. Medicines Trends 2022 Report.

Looking to the past reminds industry of great strides taken in clinical research for patients.

Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.

New regulations set stage for updated ESG considerations.

New C-Suite position emerges for more emphasis on patient centricity.

Thursday, April 21, 2022 at 10:00 EST Life sciences commercial teams need to make decisions with speed, accuracy, and confidence to personalize and optimize customer experiences, but to do so effectively requires the right data, analytics, and technology to fuel better decision-making. In this webinar, learn how you can make smarter decisions with the click of a button using behavior-changing intelligence and AI-driven recommendations

Dual efforts focused on more inclusive research and more diverse enrollment in pre- and post-approval studies.

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

Why purpose-driven firms are now more important than ever.

Cross-sector businesses are banding together to protect their intellectual property, but there’s a better way to do it.

Transition likely with looming end to emergency use authorizations tied to COVID-19 pandemic.

In episode 106, Christi Shaw, CEO of Kite, a Gilead Company, talks about how CAR T-cell therapies are impacting cancer care and the lessons she’s learned along her career path.

By acquiring Monkeys not Donkeys, QbD will strengthen its "from idea to patient" offering.

The companies are entering a license and supply agreement for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab and the radioisotope iodine-131 that is being developed for targeted conditioning to facilitate bone marrow transplant (BMT) and other cell and gene therapies.

The agreement will expand Univar Solutions' diverse excipient portfolio, helping customers with drug delivery in Brazil and Mexico.

Program looks to establish framework for agency and purchasers to “objectively rate” manufacturing sites.

This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.

Congressional bills put focus on comparator-drug access, more accurate trial and R&D cost determinations.

How early stage can help set you up for big stage.

With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.

With an increase in drug development, why purpose should be the pharma industry’s secret advantage in the global talent shortage, as the COVID-19 crisis transitions into the endemic stage.

Reshma Kewalramani, MD, FASN, chief executive officer and president of Vertex Pharmaceuticals talks about how she supports the efforts of DE&I within and outside her organization.

Robert McMahon, former president of Merck US Human Health, shares some of the challenges leaders face when grappling with how to transform their organizations to embrace DE&I.

Benchmark study across healthcare sectors measures progress in advancing women and people of color into top leadership roles.

Saving and transforming as many patients’ lives as possible has been the driving force behind Beth Seidenberg’s audacious career, where she has excelled as a doctor, researcher, and venture capitalist.

In his new role, Avallone will be responsible for growing the Evoke data team, expanding their data offerings around audience insights and analytics, and providing high-value consultancy to clients.

Award-winning Healthcare IT PR agency to collaborate with leader in modernizing payer workflows to amplify client successes and industry best practices.

Frank Li, Founder of Alliance Pharma, is transitioning leadership to Bennett but will remain a key member of the Alliance team and serve as its President and on its Board of Directors.

What will current stranglehold mean for industry down the line?

Tackling the subjective limits of value proposition.

Why their influence on employee representation matters for pharma.

Exploring the market’s emergence on the global stage.

Fresh round of discussions around health technology assessment.

Pharm Exec introduces new monthly columns.

Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.

Collaboration reinforces value of connecting proprietary and third-party data.

What’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.

Several legislative initiatives on table that would extend agency’s reach.